Results 91 to 100 of about 1,448,905 (180)

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair   +11 more
wiley   +1 more source

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

open access: yesBiomarker Insights, 2015
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis.
Nadine Kutsch   +4 more
doaj   +1 more source

In silico approaches on Bruton’s Tyrosine Kinase Inhibitors: The ligand binding mechanism and the stability of the protein-ligand complexes [PDF]

open access: yesBrazilian Journal of Pharmaceutical Sciences
Bruton’s tyrosine kinase (BTK) is a clinically validated therapeutic target for autoimmune and lymphoproliferative disorders. In this study, we conducted a comprehensive computational analysis to evaluate the binding properties, structural stability, and
Tugba Göcen   +3 more
doaj   +2 more sources

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX‐1/2 Phase 3 Studies

open access: yes
Clinical &Experimental Allergy, EarlyView.
Gordon Sussman   +15 more
wiley   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao   +4 more
wiley   +1 more source

ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation

open access: yes, 2018
Objectives: Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling downstream of multiple immunoreceptors.
Matthew Perham (5544311)   +10 more
core   +1 more source

Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
In treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...
Dominika Écsiová   +6 more
wiley   +1 more source

Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies

open access: yesReviews in Cardiovascular Medicine
Bruton's tyrosine kinase (BTK) inhibitors are important targeted drugs for treating chronic B-cell malignancies, and have played a key role in improving patient prognosis and treatment efficacy.
Haojian Gan   +8 more
doaj   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar   +6 more
wiley   +1 more source

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

open access: yes, 2019
Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by ...
Ansgar A. Wegener (7251152)   +65 more
core   +2 more sources

Home - About - Disclaimer - Privacy